Pyridine → 3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
Reaction equation
[O:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[N:3]=[C:2]1[N:10]([CH2:23][CH2:24][CH2:25][CH3:26])[CH2:11][CH2:12][C:13]1[CH:22]=[CH:21][C:16]([C:17]([NH:19][OH:20])=[NH:18])=[CH:15][CH:14]=1.N1C=CC=CC=1.[C:33]1([O:39]C(Cl)=O)C=CC=CC=1.N12CCCN=C1CCCCC2>ClCCl.C(#N)C>[O:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[N:3]=[C:2]1[N:10]([CH2:23][CH2:24][CH2:25][CH3:26])[CH2:11][CH2:12][C:13]1[CH:22]=[CH:21][C:16]([C:17]2[NH:18][C:33](=[O:39])[O:20][N:19]=2)=[CH:15][CH:14]=1Participants
7
Reactant 4
Product 1
Reagents, catalysts & solvents 2
Procedure
280 mg 4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-N-hydroxy-benzamidine were dissolved in 5 ml dichloromethane. 78 μl pyridine and 120 μl phenylchloroformate were added and the mixture stirred at room temperature for ten minutes. The mixture was diluted by the addition of 15 ml acetonitrile and 115 μl ml 1,8-Diazabicyclo[5.4.0]undec-7-ene were added. The mixture was stirred at room temperature for 10 minutes. The mixture was evaporated in vacuo and the resulting crude material was purified by reversed phase HPLC to obtain 105 mg 3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one as an amorphous lyophilisate.
Workup
- additionwere added
- stirringThe mixture was stirred at room temperature for 10 minutes
- customThe mixture was evaporated in vacuo
- customthe resulting crude material was purified by reversed phase HPLC
Sources & evidence
- ORD record
- ord-f99f8cb3233c4709940f4230b9a849d3
- Source dataset
- uspto-grants-2010_02
- Patent number
- US07655679B2
Reaction notes
Loading…